Cationic Antimicrobial Peptides Promote Microbial Mutagenesis and Pathoadaptation in Chronic Infections

English version České info

Antimicrobial peptides (AMPs) are produced by the mammalian immune system to fight invading pathogens. The best understood function of AMPs is to interact with the membranes of microbes, thereby disrupting and killing cells. However, the amount of AMP available during chronic bacterial infections may not be sufficient to kill pathogens (sub-inhibitory). In this study, we found that at sub-inhibitory levels, AMPs promote mutations in bacterial DNA, a function not previously attributed to them. In particular, we found that in the bacteria Pseudomonas aeruginosa, one AMP called LL-37 can promote mutations, which enable the bacteria to overproduce a protective sugar coating, a process called mucoid conversion. P. aeruginosa mucoid conversion is a major risk factor for those suffering from cystic fibrosis (CF), the most common lethal, heritable disease in the US. We found that LL-37 is able to produce these mutations by penetrating the bacterial cell and binding to the bacterial DNA. DNA binding disrupts normal DNA replication and allows mutations to occur. Furthermore, we observed LL-37 induced mutagenesis in processes apart from mucoid conversion, in both P. aeruginosa and E. coli. This suggests that AMP-induced mutagenesis may be important for a broad range of chronic diseases and pathogens.

Vyšlo v časopise: Cationic Antimicrobial Peptides Promote Microbial Mutagenesis and Pathoadaptation in Chronic Infections. PLoS Pathog 10(4): e32767. doi:10.1371/journal.ppat.1004083
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004083

Souhrn

Zdroje

1. BoucherR (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. European Respiratory Journal 23: 146.

2. DoullIJ (2001) Recent advances in cystic fibrosis. Archives of Disease in Childhood 85: 62–66.

3. GasparMC, CouetW, OlivierJC, PaisAACC, SousaJJS (2013) Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. European Journal of Clinical Microbiology & Infectious Diseases 32: 1–22 doi:10.1007/s10096-013-1876-y

4. FickR, SonodaF, HornickD (1992) Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Sem Resp Infec 7: 168–178.

5. GovanJR, DereticV (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60: 539–574.

6. RamseyD, WozniakD (2005) Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol 56: 309–332.

7. MartinDW, SchurrMJ, MuddMH, GovanJR, HollowayBW, et al. (1993) Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 90: 8377–8381.

8. DamronFH, GoldbergJB (2012) Proteolytic regulation of alginate overproduction in Pseudomonas aeruginosa. Mol Microbiol 84: 595–607 doi:10.1111/j.1365-2958.2012.08049.x

9. FyfeJ, GovanJ (1981) A revised chromosomal location for muc: a locus involved in the control of alginate production by mucoid Pseudomonas aeruginosa. Soc Gen Microbiol Q 8: 250–251.

10. MacGeorgeJ, KorolikV, MorganA, AsheV, HollowayB (1986) Transfer of a chromosomal locus responsible for mucoid colony morphology in Pseudomonas aeruginosa isolated from cystic fibrosis patients to P. aeruginosa PAO. J Med Microbiol 21: 331–336.

11. FlynnJ, OhmanD (1988) Cloning of genes from mucoid Pseudomonas aeruginosa which control spontaneous conversion to the alginate production phenotype. J Bacteriol 170: 1452–1460.

12. FyfeJA, GovanJR (1980) Alginate synthesis in mucoid Pseudomonas aeruginosa: a chromosomal locus involved in control. J Gen Microbiol 119: 443–450.

13. MatheeK, CiofuO, SternbergC, LindumPW, CampbellJI, et al. (1999) Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145: 1349–1357.

14. MoyanoAJ, LujánAM, ArgarañaCE, SmaniaAM (2007) MutS deficiency and activity of the error-prone DNA polymerase IV are crucial for determining mucA as the main target for mucoid conversion in Pseudomonas aeruginosa. Mol Microbiol 64: 547–559 doi:10.1111/j.1365-2958.2007.05675.x

15. SandersLH, RockelA, LuH, WozniakDJ, SuttonMD (2006) Role of Pseudomonas aeruginosa dinB-encoded DNA polymerase IV in mutagenesis. J Bacteriol 188: 8573–8585 doi:10.1128/JB.01481-06

16. CiofuO, MandsbergLF, BjarnsholtT, WassermannT, HoibyN (2010) Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156: 1108–1119 doi:10.1099/mic.0.033993-0

17. HogardtM, HeesemannJ (2010) Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. International Journal of Medical Microbiology 300: 557–562.

18. HogardtM, HobothC, SchmoldtS, HenkeC, BaderL, et al. (2007) Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 195: 70–80 doi:10.1086/509821

19. MatheeK, NarasimhanG, ValdesC, QiuX, MatewishJM, et al. (2008) Dynamics of Pseudomonas aeruginosa genome evolution. Proc Natl Acad Sci U S A 105: 3100–3105 doi:10.1073/pnas.0711982105

20. WoodLF, LeechAJ, OhmanDE (2006) Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: Roles of sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol 62: 412–426 doi:10.1111/j.1365-2958.2006.05390.x

21. WozniakD, OhmanD (1991) Pseudomonas aeruginosa AlgB, a two-component response regulator of the NtrC-family, is required for algD transcription. J Bacteriol 173: 1406–1413.

22. SandersLH, DevadossB, RajaGV, O'ConnorJ, ShengchangS, et al. (2011) Epistatic Roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in Coping with Reactive Oxygen Species-Induced DNA Damage. PLoS ONE 6: e18824 doi:10.1371/journal.pone.0018824

23. WorlitzschD, TarranR, UlrichM, SchwabU, CekiciA, et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Inves 109: 317–325.

24. SchobertM, JahnD (2010) Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung. Int J Med Microbiol 300: 549–556 doi:10.1016/j.ijmm.2010.08.007

25. XiaoW (2005) Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation. Chest 128: 2316–2326 doi:10.1378/chest.128.4.2316

26. OverhageJ, CampisanoA, BainsM, TorfsECW, RehmBHA, et al. (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76: 4176–4182 doi:10.1128/IAI.00318-08

27. FjellCD, HissJA, HancockREW, SchneiderG (2011) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11: 37–51 doi:10.1038/nrd3591

28. VandammeD, LanduytB, LuytenW, SchoofsL (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology 280: 22–35 doi:10.1016/j.cellimm.2012.11.009

29. SørensenOE, FollinP, JohnsenAH, CalafatJ, TjabringaGS, et al. (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951–3959.

30. BalsR, WeinerDJ, MeegallaRL, AccursoF, WilsonJM (2001) Salt-Independent Abnormality of Antimicrobial Activity in Cystic Fibrosis Airway Surface Fluid. Am J Respir Cell Mol Biol 25: 21.

31. FelgentreffK, BeisswengerC, GrieseM, GulderT, BringmannG, et al. (2006) The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 27: 3100–3106 doi:10.1016/j.peptides.2006.07.018

32. BuckiR, ByfieldFJ, JanmeyPA (2007) Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 29: 624–632 doi:10.1183/09031936.00080806

33. SpencerDH, KasA, SmithEE, RaymondCK, SimsEH, et al. (2003) Whole-Genome Sequence Variation among Multiple Isolates of Pseudomonas aeruginosa. J Bacteriol 185: 1316–1325 doi:10.1128/JB.185.4.1316-1325.2003

34. AnthonyM, RoseB, PeglerMB, ElkinsM, ServiceH, et al. (2002) Genetic Analysis of Pseudomonas aeruginosa Isolates from the Sputa of Australian Adult Cystic Fibrosis Patients. Journal of Clinical Microbiology 40: 2772–2778 doi:10.1128/JCM.40.8.2772-2778.2002

35. BragonziA, WiehlmannL, KlockgetherJ, CramerN, WorlitzschD, et al. (2006) Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 152: 3261–3269 doi:10.1099/mic.0.29175-0

36. BoucherJ, YuH, MuddM, DereticV (1997) Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infection and Immunity 65: 3838–3846.

37. ImlayJA (2008) Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem 77: 755–776 doi:10.1146/annurev.biochem.77.061606.161055

38. WagnerJ, GruzP, KimS, YamadaM, MatsuiK, et al. (1999) The dinB gene encodes a novel E. coli DNA polymerase, DNA pol IV, involved in mutagenesis. Molecular Cell 4: 281–286.

39. MillerC (2004) SOS Response Induction by Beta-Lactams and Bacterial Defense Against Antibiotic Lethality. Science 305: 1629–1631 doi:10.1126/science.1101630

40. HeJ, FurmanskiP (1995) Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373: 721–724 doi:10.1038/373721a0

41. HsuCH (2005) Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Research 33: 4053–4064 doi:10.1093/nar/gki725

42. MarchandC, KrajewskiK, LeeHF, AntonyS, JohnsonAA, et al. (2006) Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Research 34: 5157–5165 doi:10.1093/nar/gkl667

43. ParkCB, KimHS, KimSC (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244: 253–257 doi:10.1006/bbrc.1998.8159

44. SubbalakshmiC, SitaramN (1998) Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 160: 91–96.

45. SeilM, NagantC, DehayeJP, VandenbrandenM, LensinkMF (2010) Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals 3: 3435–3460.

46. LandeR, GregorioJ, FacchinettiV, ChatterjeeB, WangY-H, et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564–569 doi:10.1038/nature06116

47. SochackiKA, BarnsKJ, BuckiR, WeisshaarJC (2011) Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc Natl Acad Sci U S A 108: E77–E81 doi:10.1073/pnas.1101130108

48. ZasloffM (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389–395 doi:10.1038/415389a

49. ShaiY (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes 1462: 55–70 doi:10.1016/S0005-2736(99)00200-X

50. MatsuzakiK (1999) Why and how are peptide–lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1462: 1–10 doi:10.1016/S0005-2736(99)00197-2

51. YangL, WeissTM, LehrerRI, HuangHW (2000) Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 79: 2002–2009 doi:10.1016/S0006-3495(00)76448-4

52. LiL, ShiY, CheserekMJ, SuG, LeG (2013) Antibacterial activity and dual mechanisms of peptide analog derived from cell-penetrating peptide against Salmonella typhimurium and Streptococcus pyogenes. Appl Microbiol Biotechnol 97: 1711–1723 doi:10.1007/s00253-012-4352-1

53. FriedbergE, LehmannA, FuchsR (1995) Trading Places: How Do DNA Polymerases Switch During Translesion DNA Synthesis? Molecular Cell 18: 499–505 doi:10.1016/j.molcel.2005.03.032

54. KeppleKV, PatelN, SalamonP, SegallAM (2008) Interactions between branched DNAs and peptide inhibitors of DNA repair. Nucleic Acids Research 36: 5319–5334 doi:10.1093/nar/gkn512

55. Su DLWAMSLeo Y (2010) An Antimicrobial Peptide That Targets DNA Repair Intermediates In Vitro Inhibits Salmonella Growth within Murine Macrophages. Antimicrobial Agents and Chemotherapy 54: 1888 doi:10.1128/AAC.01610-09

56. Induction of group A Streptococcus virulence by a human antimicrobial peptide (2008) Induction of group A Streptococcus virulence by a human antimicrobial peptide. 105: 16755–16760.

57. StockleyRA (2002) Neutrophils and the Pathogenesis of COPD. Chest 121: 151S–155S doi:_10.1378/chest.121.5_suppl.151S

58. HoenderdosK, CondliffeA The Neutrophil in Chronic Obstructive Pulmonary Disease. Too Little, Too Late or Too Much, Too Soon? Am J Respir Cell Mol Biol 48: 531–539 doi:0.1165/rcmb.2012-0492TR

59. MurphyTF, BrauerAL, EschbergerK, LobbinsP, GroveL, et al. (2008) Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 177: 853–860 doi:10.1164/rccm.200709-1413OC

60. KonstanMW, HilliardKA, NorvellTM, BergerM (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150: 448–454 doi:10.1164/ajrccm.150.2.8049828

61. DhoogheB, NoëlS, HuauxF, LealT (2013) Lung inflammation in Cystic Fibrosis: Pathogenesis and novel therapies. Clin Biochem pii S0009-9120(13)00605-X doi:10.1016/j.clinbiochem.2013.12.020

62. McCaugheyG, GilpinDF, ElbornJS, TunneyMM (2013) The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Review of Respiratory Medicine 7: 385–396.

63. MercerDK, O'NeilDA (2013) Peptides as the next generation of anti-infectives. Future Medicinal Chemistry 5: 315–337 doi:10.4155/fmc.12.213

64. MishraM, ByrdMS, SergeantS, AzadAK, ParsekMR, et al. (2012) Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol 14: 95–106 doi:10.1111/j.1462-5822.2011.01704.x

65. QiuD, DamronFH, MimaT, SchweizerHP, YuHD (2008) PBAD-Based Shuttle Vectors for Functional Analysis of Toxic and Highly Regulated Genes in Pseudomonas and Burkholderia spp. and Other Bacteria. Appl Environ Microbiol 74: 7422–7426 doi:10.1128/AEM.01369-08

66. KnutsonC, JeanesA (1968) A new modification of the carbazole analysis: application to heteropolysaccharides. Anal Biochem 24: 470–481.

67. MaS, SelvarajU, OhmanDE, QuarlessR, HassettDJ, et al. (1998) Phosphorylation-independent activity of the response regulators AlgB and AlgR in promoting alginate biosynthesis in mucoid Pseudomonas aeruginosa. J Bacteriol 180: 956–968.

68. ParragaA, BellsolellL, Ferré-D'AmaréAR, BurleySK (1998) Co-crystal structure of sterol regulatory element binding protein 1a at 2.3 å resolution. Structure 6: 661–672 doi:10.1016/S0969-2126(98)00067-7

69. LuriaSE, DelbrückM (1943) Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics 28: 491–511.